Skip to content

Magnesium Sulfate In Adverse With Nifedipine In suppression preterm labor In Pregnant With Preterm Labor

Magnesium Sulfate In Adverse With Nifedipine In Suppression Preterm labor In Pregnant With Preterm Labor

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201201308878N1
Enrollment
80
Registered
2012-05-05
Start date
2012-04-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preterm labor. Preterm labour without delivery

Interventions

Intervention 1: First group (A) will be giving 4 gram Magnesium Sulfate as a loading dose then countining 2 gram every hour until 48 hours(positive Patella reflex ,at least 12 times respiratory rates
Treatment - Drugs
First group (A) will be giving 4 gram Magnesium Sulfate as a loading dose then countining 2 gram every hour until 48 hours(positive Patella reflex ,at least 12 times respiratory rates,urine output at
The other group will be giving Nifedipine tablet(20mg) after half an hour will be given other 20 mg of Nifedipine tablet,if contractions persist ,giving 20 mg Nifedipin will be countining every 3-8

Sponsors

Tabriz University Of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
14 Years to 45 Years

Inclusion criteria

Inclusion criteria: Criteria include more than 6 contractions per hour resulting in a demonstrated cervical change or presumed prior cervical change (transvaginal cervical length 50% cervical effacement, or cervical dilation =2 cm) ;Gestational ages are between 26-34 ; Bloody show ; Nully fetus pregnant ; Intact membranes ; BP>90 mmhg in Nifedipine group exclude criteria Oligohydramnios and polyhydramnios ;Nonreactive nonstress test results ;Positive contraction stress test results ; Absent or reversed diastolic flow upon Doppler examination of umbilical blood flow ; Repetitive severe variable decelerations ;Significant vaginal bleeding consistent with abruption and placenta previa ; PPROM ;Multi fetus pregnancy ;BP<90 mmhg in Nifedipine group ; Intrauterine infection ; Pyelonefrites ;Preeclampse and GTM and anomalies

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Effecement. Timepoint: In addmission. Method of measurement: Vaginal examination.;Dillatation. Timepoint: In admmision. Method of measurement: Vaginal examination.;Length and diuration of contractions. Timepoint: Every 10 minute. Method of measurement: Abdominal tough of uterus.

Secondary

MeasureTime frame
Feeling of fetal movment by mother. Timepoint: In an hour. Method of measurement: Abdominal touching.;Unreliable paterns of fetal heart rate. Timepoint: In 20 minnutes. Method of measurement: Record by monitoring devices.;Newborn Apgar. Timepoint: In first and fifth min. Method of measurement: Apgars score.;ABG of umblical cord blood. Timepoint: After birth. Method of measurement: ABG devices.;Meconium. Timepoint: After birth. Method of measurement: Finding meconium on neuborn skin or amniotic fluid or amblical cord.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFereshteh Fartash

Nursing and Midwifery University of Tabriz

fereshtefartash@gmail.comfereshtehfartash@yahoo.com+98 41 1666 1428

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026